Science
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo – Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies w
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reportspreclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.
The study, Mitochondrial targeted meganuclease as a platform to eliminate…
-
Noosa News14 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News13 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News22 hours agoCountdown on for Noosa Eat & Drink Festival 2025